Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|4|445-456

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.4, 2015-08, pp. : 445-456

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 734-736

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hybrid Cytogenetics of Chronic Lymphocytic Leukemia and Follicular Cell Lymphoma in a Case of Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 116, Iss. 2, 2006-08 ,pp. : 150-152

Karger

Access to resources Recommend Favorite

Progressive multi‐focal leucoencephalopathy among ibrutinib‐treated persons with chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 301-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 125-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 145-149

John Wiley & Sons Inc

Access to resources Recommend Favorite